Genetics/NNP Institute/NNP Inc./NNP ,/, Cambridge/NNP ,/, Mass./NNP ,/, said/VBD 0/-NONE- it/PRP was/VBD awarded/VBN *-4/-NONE- U.S./NNP patents/NNS for/IN Interleukin-3/NN and/CC bone/NN morphogenetic/JJ protein/NN ./.
The/DT patent/NN for/IN Interleukin-3/NN covers/VBZ materials/NNS and/CC methods/NNS used/VBN */-NONE- */-NONE- to/TO make/VB the/DT human/JJ blood/NN cell/NN growth/NN factor/NN via/IN recombinant/JJ DNA/NNP technology/NN ./.
Sandoz/NNP Ltd./NNP has/VBZ licensed/VBN certain/JJ manufacturing/NN and/CC marketing/NN rights/NNS for/IN Interleukin-3/NN from/IN Genetics/NNP Institute/NNP and/CC is/VBZ conducting/VBG preclinical/JJ studies/NNS with/IN it/PRP ./.
Interleukin-3/NN may/MD help/VB in/IN */-NONE- treating/VBG blood/NN cell/NN deficiencies/NNS associated/VBN */-NONE- with/IN cancer/NN treatment/NN ,/, bone/NN marrow/NN transplants/NNS and/CC other/JJ blood-cell/NN disorders/NNS ,/, Genetics/NNP Institute/NNP said/VBD 0/-NONE- *T*-1/-NONE- ./.
The/DT second/JJ patent/NN describes/VBZ bone/NN morphogenetic/JJ protein-1/NN ,/, a/DT substance/NN that/WDT *T*-2/-NONE- can/MD induce/VB formation/NN of/IN new/JJ cartilage/NN ./.
The/DT patent/NN covers/VBZ BMP-1/NN type/NN proteins/NNS and/CC pharmaceutical/JJ compositions/NNS and/CC methods/NNS for/IN */-NONE- treating/VBG bone/NN or/CC cartilage/NN defects/NNS ,/, Genetics/NNP Institute/NNP said/VBD 0/-NONE- *T*-1/-NONE- ./.
The/DT company/NN added/VBD that/IN it/PRP has/VBZ filed/VBN patent/NN applications/NNS ``/`` on/IN a/DT large/JJ number/NN of/IN different/JJ BMP/NN proteins/NNS ''/'' and/CC the/DT patent/NN on/IN BMP-1/NN is/VBZ the/DT first/JJ 0/-NONE- it/PRP has/VBZ received/VBN *T*-1/-NONE- ./.
BMP/NN products/NNS may/MD be/VB useful/JJ in/IN fracture/NN healing/NN and/CC in/IN */-NONE- treating/VBG bone/NN loss/NN associated/VBN */-NONE- with/IN periodontal/JJ disease/NN and/CC certain/JJ cancers/NNS ,/, the/DT company/NN said/VBD 0/-NONE- *T*-1/-NONE- ./.

